

Response to Article “Autophagy Inhibits Inflammation via Down-Regulation of p38 MAPK/mTOR Signaling Cascade in Endothelial Cells” [Response to Letter]

Ling Zhou¹, Juanjuan Wang¹, Hui Hou¹, Jiao Li¹, Juan Li¹, Jiannan Liang¹, Junqin Li¹, Xuping Niu¹, Ruixia Hou¹, Kaiming Zhang^{1,2} 

¹Shanxi Key Laboratory of Stem Cells for Immunological Dermatitis, Institute of Dermatology, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, People's Republic of China; ²Shanxi Key Laboratory of Stem Cells for Immunological Dermatitis, Institute of Dermatology, Taiyuan Central Hospital, Taiyuan, People's Republic of China

Correspondence: Kaiming Zhang, Email zhangkaiming@sina.com

Dear editor

Thank you for your valuable comments on the paper. For the control problem, we made a blank control in the experiment, namely the control in the paper. Meanwhile, we also tested the indexes of the cells treated by the single autophagy inhibitor CQ and the p38 MAPK inhibitor SB203580. The results do not affect the final results and conclusions of the paper, but due to the space, we did not write the relevant results in the paper. In further studies we will add appropriate negative controls.

Disclosure

The authors report no conflicts of interest in this communication.

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Clinical, Cosmetic and Investigational Dermatology ‘letters to the editor’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Clinical, Cosmetic and Investigational Dermatology editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Clinical, Cosmetic and Investigational Dermatology

Dovepress

Publish your work in this journal

Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access, online journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. This journal is indexed on CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal>

<https://doi.org/10.2147/CCID.S414606>

Received: 28 March 2023
Accepted: 28 March 2023
Published: 3 April 2023

Clinical, Cosmetic and Investigational Dermatology 2023:16 859

859



© 2023 Zhou et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<http://creativecommons.org/licenses/by-nc/3.0/>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<https://www.dovepress.com/terms.php>).